Richcore Lifesciences is a research-driven biotech company committed to making medicines safer by offering reliable,cost effective, and high-quality recombinant proteins and enzymes that replace animal derived components used in the manufacturing of medicines. Richcore offers Not of Animal Origin (NOA) recombinant proteins for regenerative medicine, stem cell research, and biotherapeutics such as insulin and vaccine manufacturing and cosmetic applications. The company has already enabled several global manufacturers of insulin and vaccines to do away with animal derived components and produce billions of doses of safer medicines by using their products. At the root of Richcore's innovation is the vision and commitment to create safer, more reliable, and more sustainable solutions to tackle current health problems. Richcore has recently launched the most cost effective and affordable recombinant human albumin, which is expected to replace Human Serum Albumin (blood plasma) for therapeutic use once approved. In both 2009 and 2012, Richcore received $6 million in Series A and B funding.
Subramani Ramachandrappa (Chairman and Managing Director at Richcore India) has been an Unreasonable Fellow since May 2017 and most recently participated in The Unreasonable Impact COVID-19 Response Exclusive Summit, created with Barclays.